Global University Venturing

This is the first in a series of quarterly publications for the Global Health Council looking at drug development, healthcare providers such as hospitals and digital health, payments and patient wellness. This first article looks at the implications of the disease treatments coming out of advanced research and artificial intelligence and the broader shift to digitalisation in healthcare. The next issue will focus on the providers of healthcare.

The spinout’s technology was fundamental to Oxford’s covid vaccine, prompting OSI and Future Planet Capital to back a $168m round.

IBM Ventures participated in a $20m round for the neurological disease diagnostics technology spinout of Tel Aviv University.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Miyako Capital has contributed to a series A round for the cancer vaccine developer, which expanded to Japan last year.

The money will fund the progress of the University of London-linked precision medicine developer's lead drug candidate into the clinic.

Osaka spinout Cuorips has added $14.7m to its coffers from investors including vehicles for the institution and Kyoto University, just three months after collecting $19.3m.

The Keio University-backed digital medicine developer has secured $19.3m from a consortium including several Japanese corporations.

Monthly analysis: February

Where do you begin to summarise a year that has been the most challenging on a global scale in living memory?

RA Capital Management and Rock Springs Capital have co-led a series B round for the gene editing technology developer spun out of Stanford six months ago.